Department of Urinary Surgery, Gongli Hospital, Second Military Medical University (Naval Medical University), 219 Miaopu Road, Shanghai, 200135, China.
Department of Urology, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou, 213000, Jiangsu, China.
Cell Death Differ. 2021 Mar;28(3):932-951. doi: 10.1038/s41418-020-00626-6. Epub 2020 Oct 2.
Although the interaction between tumors and tumor-associated macrophages (TAMs) has been reported to facilitate the targeted drug resistance and progression of clear cell renal cell carcinoma (ccRCC), the related mechanisms remain unknown. Here, we report that SOX17 serves as a novel tumor suppressor in ccRCC and a positive regulatory loop, SOX17/YAP/TEAD1/CCL5/CCR5/STAT3, facilitates the ccRCC-TAM interaction. SOX17 expression was commonly downregulated and negatively correlated with TAM infiltration in ccRCC specimens, and the integration of SOX17 and TAMs with the existing clinical indicators TNM stage or SSIGN score achieved better accuracy for predicting the prognosis of ccRCC patients. Mechanistically, SOX17 knockdown activated YAP signaling by promoting the transcription and nuclear distribution of YAP, which recruited TEAD1 to trigger CCL5 transcription. Then, CCL5 educated macrophages toward TAMs, which reciprocally enhanced ccRCC progression through CCL5/CCR5 and activated STAT3/SOX17/YAP. However, SOX17 overexpression in ccRCC achieved the opposite effect. Thus, a positive regulatory loop, SOX17/YAP/TEAD1/CCL5/CCR5/STAT3, was identified in the ccRCC-TAM interaction. Furthermore, targeting tumor-TAM interactions by blocking this positive regulatory network impaired the metastasis and targeted drug resistance of ccRCC in in vivo mouse models of lung metastasis and orthotopic ccRCC. These findings provide a new mechanism underlying the tumor-TAM interplay in ccRCC progression and present a potential target for inhibiting targeted drug resistance and metastasis in advanced ccRCC.
尽管已经报道了肿瘤与肿瘤相关巨噬细胞(TAMs)之间的相互作用促进了透明细胞肾细胞癌(ccRCC)的靶向药物耐药和进展,但相关机制尚不清楚。在这里,我们报告 SOX17 作为 ccRCC 的一种新型肿瘤抑制因子,以及一个正调控环 SOX17/YAP/TEAD1/CCL5/CCR5/STAT3,促进了 ccRCC-TAM 相互作用。SOX17 表达普遍下调,与 ccRCC 标本中 TAM 浸润呈负相关,SOX17 与 TAMs 的整合与现有的临床指标 TNM 分期或 SSIGN 评分相结合,能够更好地预测 ccRCC 患者的预后。从机制上讲,SOX17 敲低通过促进 YAP 的转录和核分布激活 YAP 信号,从而募集 TEAD1 触发 CCL5 转录。然后,CCL5 将巨噬细胞向 TAMs 教育,TAMs 通过 CCL5/CCR5 相互作用增强 ccRCC 进展,并激活 STAT3/SOX17/YAP。然而,SOX17 在 ccRCC 中的过表达则产生相反的效果。因此,在 ccRCC-TAM 相互作用中鉴定出一个正调控环 SOX17/YAP/TEAD1/CCL5/CCR5/STAT3。此外,通过阻断这个正调控网络靶向肿瘤-TAM 相互作用,在体内肺转移和原位 ccRCC 小鼠模型中损害了 ccRCC 的转移和靶向药物耐药性。这些发现为 ccRCC 进展中肿瘤-TAM 相互作用提供了一个新的机制,并为抑制晚期 ccRCC 的靶向药物耐药性和转移提供了一个潜在的靶点。